tirzepatide glycine cyanocobalamin with + B12 Tirzepatide B12 or Glycine Vial

Research from the Journal of Clinical Investigation shows tirzepatide binds the GIP receptor with affinity similar to native GIP (Ki of 0.135), while its GLP-1 receptor affinity is roughly five-fold weaker than native GLP-1 (Ki of 4.23)

It also needs to be more thoroughly researched to determine its effectiveness.

Any consideration of reducing or discontinuing PAP therapy due to weight loss should occur only under the supervision of a sleep medicine specialist and following objective reassessment with polysomnography or home sleep apnea testing

The injection is typically administered once a week and is preferred by those looking for less daily commitment